Audio and video technology company Dolby Laboratories (NYSE: DLB) missed Wall Street’s revenue expectations in Q2 CY2026, with sales falling 3.3% year on year to $305 million. On the other hand, next quarter’s outlook exceeded expectations with revenue guided to $377 million at the midpoint, or 7.4% above analysts’ estimates. Its non-GAAP profit of $0.69 per share was 3% above analysts’ consensus estimates.
Is now the time to buy Dolby Laboratories? Find out by accessing our full research report, it’s free.
Dolby Laboratories (DLB) Q2 CY2026 Highlights:
- Revenue: $305 million vs analyst estimates of $311.3 million (3.3% year-on-year decline, 2% miss)
- Adjusted EPS: $0.69 vs analyst estimates of $0.67 (3% beat)
- Revenue Guidance for Q3 CY2026 is $377 million at the midpoint, above analyst estimates of $351 million
- Management lowered its full-year Adjusted EPS guidance to $4.33 at the midpoint, a 1.1% decrease
- Operating Margin: 11.3%, down from 15.1% in the same quarter last year
- Market Capitalization: $4.97 billion
"We continue to execute against our full-year objectives, and we are building momentum across several of our key growth areas," said Kevin Yeaman, President and CEO, Dolby Laboratories.
Company Overview
Known for its iconic "D" logo that appears before countless movies and TV shows, Dolby Laboratories (NYSE: DLB) designs and licenses audio and video technologies that enhance entertainment experiences in movies, TV shows, music, and other media.
Revenue Growth
Examining a company’s long-term performance can provide clues about its quality. Any business can have short-term success, but a top-tier one grows for years. Regrettably, Dolby Laboratories’s sales grew at a weak 1.3% compounded annual growth rate over the last five years. This fell short of our benchmarks and is a rough starting point for our analysis.
Long-term growth is the most important, but within software, a half-decade historical view may miss new innovations or demand cycles. Dolby Laboratories’s annualized revenue growth of 3.7% over the last two years is above its five-year trend, which is encouraging. 
This quarter, Dolby Laboratories missed Wall Street’s estimates and reported a rather uninspiring 3.3% year-on-year revenue decline, generating $305 million of revenue. Company management is currently guiding for a 22.8% year-on-year increase in sales next quarter.
Looking further ahead, sell-side analysts expect revenue to grow 6.8% over the next 12 months. While this projection indicates its newer products and services will catalyze better top-line performance, it is still below average for the sector.
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
Customer Acquisition Efficiency
The customer acquisition cost (CAC) payback period represents the months required to recover the cost of acquiring a new customer. Essentially, it’s the break-even point for sales and marketing investments. A shorter CAC payback period is ideal, as it implies better returns on investment and business scalability.
Dolby Laboratories’s recent customer acquisition efforts haven’t yielded returns as its CAC payback period was negative this quarter, meaning its incremental sales and marketing investments outpaced its revenue. The company’s inefficiency indicates it operates in a highly competitive environment where there is little differentiation between Dolby Laboratories’s products and its peers.
Key Takeaways from Dolby Laboratories’s Q2 Results
We were impressed by Dolby Laboratories’s optimistic revenue guidance for next quarter, which blew past analysts’ expectations. We were also glad its full-year revenue guidance slightly exceeded Wall Street’s estimates. On the other hand, its revenue missed and its EPS guidance for next quarter was in line with Wall Street’s estimates. Zooming out, we think this was a mixed quarter. Investors were likely hoping for more, and shares traded down 1.6% to $50.89 immediately following the results.
Big picture, is Dolby Laboratories a buy here and now? If you’re making that decision, you should consider the bigger picture of valuation, business qualities, as well as the latest earnings. We cover that in our actionable full research report which you can read here (it’s free).
